Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200577703> ?p ?o ?g. }
- W4200577703 abstract "Short stature is the most consistent characteristic feature of Turner syndrome (TS). To improve final heights of children with TS effectively, it is important to provide them with early and appropriate treatment using growth hormone (GH). The objective of this study was to assess the efficacy and safety of a new recombinant human GH, Growtropin®-II (DA-3002, Dong-A ST Co., Ltd) versus a comparator (Genotropin®, Pfizer Inc.) for Korean children with TS.This open-label, active-controlled, parallel-group, randomized controlled phase III trial was conducted at 11 hospitals in Korea. Eligible patients (n = 58) were randomized to two groups: 1) DA-3002 group (administrated with DA-3002 at 0.14 IU [0.0450-0.050 mg] /kg/day); and 2) comparator group (administrated with the comparator at 0.14 IU [0.0450-0.050 mg] /kg/day).The change from baseline in annualized height velocity (HV) after a 52-week treatment period was 4.15 ± 0.30 cm/year in the DA-3002 group and 4.34 ± 0.29 cm/year in the comparator group. The lower bound of 95% two-sided confidence interval for group difference in the change of annualized HV (- 1.02) satisfied the non-inferiority margin (- 1.5). The change in height standard deviation score (HtSDS) at 52-week was 0.70 ± 0.23 for the DA-3002 group and 0.66 ± 0.39 for the comparator group, showing no significant (p = 0.685) difference between the two groups. The change of skeletal maturity defined as change in bone age/change in chronological age between the two groups was not significantly different (1.25 ± 0.58 for the DA-3002 group and 1.47 ± 0.45 for the comparator group, p = 0.134). Changes from baseline in serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) after 52 weeks of treatment did not differ significantly between the two groups (p = 0.565 and p = 0.388, respectively) either. The occurrence of adverse events was not statistically different between groups.This study demonstrates that the efficacy and safety of GH treatment with DA-3002 in children with TS are comparable with those of the comparator. It is expected to analysis the long-term effect of DA-3002 on the increase of final adult height in children with TS and possible late-onset complications in the future.The study was registered at ClinicalTrials.gov. ClinicalTrials.gov identifier: NCT01813630 (19/03/2013)." @default.
- W4200577703 created "2021-12-31" @default.
- W4200577703 creator A5014016038 @default.
- W4200577703 creator A5014168443 @default.
- W4200577703 creator A5020700790 @default.
- W4200577703 creator A5031163211 @default.
- W4200577703 creator A5034464002 @default.
- W4200577703 creator A5040250492 @default.
- W4200577703 creator A5042083758 @default.
- W4200577703 creator A5044020391 @default.
- W4200577703 creator A5045381118 @default.
- W4200577703 creator A5052219459 @default.
- W4200577703 creator A5058503965 @default.
- W4200577703 creator A5074434351 @default.
- W4200577703 creator A5089460797 @default.
- W4200577703 date "2021-12-01" @default.
- W4200577703 modified "2023-10-17" @default.
- W4200577703 title "Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial" @default.
- W4200577703 cites W1853315177 @default.
- W4200577703 cites W1963970287 @default.
- W4200577703 cites W1977079615 @default.
- W4200577703 cites W2013492072 @default.
- W4200577703 cites W2019867349 @default.
- W4200577703 cites W2021094557 @default.
- W4200577703 cites W2032211298 @default.
- W4200577703 cites W2045509368 @default.
- W4200577703 cites W2051644961 @default.
- W4200577703 cites W2069347803 @default.
- W4200577703 cites W2071070295 @default.
- W4200577703 cites W2071114725 @default.
- W4200577703 cites W2077648664 @default.
- W4200577703 cites W2081983661 @default.
- W4200577703 cites W2092019905 @default.
- W4200577703 cites W2103284733 @default.
- W4200577703 cites W2105515939 @default.
- W4200577703 cites W2109542915 @default.
- W4200577703 cites W2112109195 @default.
- W4200577703 cites W2114748331 @default.
- W4200577703 cites W2119751587 @default.
- W4200577703 cites W2122418767 @default.
- W4200577703 cites W2130049764 @default.
- W4200577703 cites W2157381937 @default.
- W4200577703 cites W2166383227 @default.
- W4200577703 cites W2169338958 @default.
- W4200577703 cites W2220789576 @default.
- W4200577703 cites W2299365467 @default.
- W4200577703 cites W2735815275 @default.
- W4200577703 cites W2778423850 @default.
- W4200577703 cites W2779029514 @default.
- W4200577703 cites W2792324931 @default.
- W4200577703 cites W2793290189 @default.
- W4200577703 cites W2808015078 @default.
- W4200577703 cites W2971849597 @default.
- W4200577703 cites W2988507184 @default.
- W4200577703 cites W3004734471 @default.
- W4200577703 cites W3149447725 @default.
- W4200577703 cites W3167509936 @default.
- W4200577703 doi "https://doi.org/10.1186/s12902-021-00904-5" @default.
- W4200577703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34893062" @default.
- W4200577703 hasPublicationYear "2021" @default.
- W4200577703 type Work @default.
- W4200577703 citedByCount "0" @default.
- W4200577703 crossrefType "journal-article" @default.
- W4200577703 hasAuthorship W4200577703A5014016038 @default.
- W4200577703 hasAuthorship W4200577703A5014168443 @default.
- W4200577703 hasAuthorship W4200577703A5020700790 @default.
- W4200577703 hasAuthorship W4200577703A5031163211 @default.
- W4200577703 hasAuthorship W4200577703A5034464002 @default.
- W4200577703 hasAuthorship W4200577703A5040250492 @default.
- W4200577703 hasAuthorship W4200577703A5042083758 @default.
- W4200577703 hasAuthorship W4200577703A5044020391 @default.
- W4200577703 hasAuthorship W4200577703A5045381118 @default.
- W4200577703 hasAuthorship W4200577703A5052219459 @default.
- W4200577703 hasAuthorship W4200577703A5058503965 @default.
- W4200577703 hasAuthorship W4200577703A5074434351 @default.
- W4200577703 hasAuthorship W4200577703A5089460797 @default.
- W4200577703 hasBestOaLocation W42005777031 @default.
- W4200577703 hasConcept C126322002 @default.
- W4200577703 hasConcept C168563851 @default.
- W4200577703 hasConcept C2777871287 @default.
- W4200577703 hasConcept C2779683239 @default.
- W4200577703 hasConcept C44249647 @default.
- W4200577703 hasConcept C71924100 @default.
- W4200577703 hasConcept C89551170 @default.
- W4200577703 hasConceptScore W4200577703C126322002 @default.
- W4200577703 hasConceptScore W4200577703C168563851 @default.
- W4200577703 hasConceptScore W4200577703C2777871287 @default.
- W4200577703 hasConceptScore W4200577703C2779683239 @default.
- W4200577703 hasConceptScore W4200577703C44249647 @default.
- W4200577703 hasConceptScore W4200577703C71924100 @default.
- W4200577703 hasConceptScore W4200577703C89551170 @default.
- W4200577703 hasIssue "1" @default.
- W4200577703 hasLocation W42005777031 @default.
- W4200577703 hasLocation W42005777032 @default.
- W4200577703 hasLocation W42005777033 @default.
- W4200577703 hasLocation W42005777034 @default.
- W4200577703 hasOpenAccess W4200577703 @default.
- W4200577703 hasPrimaryLocation W42005777031 @default.
- W4200577703 hasRelatedWork W1671866093 @default.
- W4200577703 hasRelatedWork W1967804466 @default.